Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Comment by RetailRubeon Oct 30, 2012 1:21pm
141 Views
Post# 20540004

RE: Diagnostic Advantage

RE: Diagnostic Advantage

I watched the movie "All the President's Men" on the weekend.  This was about Woodward and Bernstein at the Washington Post and how they investigated and exposed the Watergate Scandal, leading to Nixon's resignation.  I was impressed by how journalists get 2 independent sources to confirm each fact.  And how Ben Bradlee insisted on 3 sources for some of the bigger stories before he would allow it to be published.

 

And how high are the journalistic standards of this article?  Well, umm ...

  1. Did the writer confirm the "success in the marketplace" by checking the revenue line in the Diagnocure financial statements?
  2. Did the writer confirm with Signal Genetics that Signal is "funding the clinical trial" on GCC?
  3. Did the writer read Diagnocure's press releases in the last 90 days?
  4. Did the writer talk to any shareholders about Fradet "succeeding in his objective of inventing valued cancer tests".

 

The writer succeeded in describing the technology correctly and in great detail, but I think the story is a little one-sided.  It almost sounds like Diagnocure paid for the article to be written and published.  CUR2004, how did you discover this article so quickly?  It was published only yesterday.  Do you work for Diagnocure?

 

<< Previous
Bullboard Posts
Next >>